Everything below concerns pituitary axis. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-03-09. Numbers and descriptions here follow the published literature rather than marketing material.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
The peptide is synthesized chemically rather than extracted from biological sources. Solid-phase synthesis builds the chain from the C-terminus toward the N-terminus, after which the hexenoyl group is attached. Purity is typically assessed by high-performance liquid chromatography, and identity is confirmed by mass spectrometry. Regulatory review of the finished product focuses on these analytical controls, since small deviations in sequence or modification can change biological activity. Questions about long-term effects on the pituitary axis remain areas of continued investigation.
| Property | Value | Notes |
|---|---|---|
| Drug class | Peptide hormone analog | Acts at the growth hormone-releasing hormone receptor |
| Receptor | Growth hormone-releasing hormone receptor | G protein-coupled; raises cyclic AMP in somatotrophs |
| Key mediator | Insulin-like growth factor 1 | Increases with repeated administration |
| Main studied population | Adults with HIV-associated lipodystrophy | Trials measured visceral adipose tissue by imaging |
| Route | Subcutaneous injection | Given once daily in clinical use |
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Growth of protein crystals Improved semiconductor wafers Micro-encapsulation As the infrastructure is developed and the cost of assembly drops, some of the manufacturing capacity can be directed toward the development of expanded facilities in space, including larger scale manufacturing plants. These will likely require the use of lunar and asteroid materials, and so follow the development of mining bases. Rock is the simplest product, and at minimum is useful for radiation shielding. It can also be subsequently processed to extract elements for various uses. Water from lunar sources, Near Earth Asteroids or Martian moons is thought to be relatively cheap and simple to extract, and gives adequate performance for many manufacturing and material shipping purposes. Separation of water into hydrogen and oxygen can be easily performed in small scale, but some scientists believe that this will not be performed on any large scale initially due to the large quantity of equipment and electrical energy needed to split water and liquify the resultant gases. Water used in steam rockets gives a specific impulse of about 190 seconds; less than half that of hydrogen/oxygen, but this is adequate for delta-v's that are found between Mars and Earth. Water is useful as a radiation shield and in many chemical processes. Ceramics made from lunar or asteroid soil can be employed for a variety of manufacturing purposes. These uses include various thermal and electrical insulators, such as heat shields for payloads being delivered to the Earth's surface.
The Centre, the BVP and the DNVP jointly supported legislation to expand religious schools. In the same year, Wilhelm Marx was the Centre's candidate in the presidential elections. In the second round, combining the support of the Weimar coalition parties, he gained 45.3% of the vote and finished a close second to the victorious right-wing candidate Paul von Hindenburg with 48.3%. In May 1926 Chancellor Luther resigned and Marx again assumed the chancellorship. In June 1928, the general elections resulted in losses for the government parties and in gains for the Social Democrats and the Communists. The Grand Coalition of 1923 was revived, this time including the BVP and the Social Democrat Hermann Müller became chancellor. During the years of the Weimar Republic, debates about the Catholic character of the party, as described above, persisted. The left wing of the party, led by Erzberger and Wirth, had close ties to the Catholic workers' associations led by Joseph Joos. Some politicians on the right wing of the party, including Heinrich Brauns and Franz von Papen, advocated a move towards the right and a closer cooperation with the national movements. The middle-ground emphasised their loyalty to the Church and rejected both extremes. To mediate the tension between the wings and to strengthen their ties with the Bishops, the party in September 1928 did not elect the two favourites Joseph Joos and Adam Stegerwald, but rather the cleric Ludwig Kaas as chairman.
==== Carbon-nitrogen ==== Monoamine oxidase (MAO) is an extensively studied flavoenzyme due to its biological importance with the catabolism of norepinephrine, serotonin and dopamine. MAO oxidizes primary, secondary and tertiary amines, which nonenzymatically hydrolyze from the imine to aldehyde or ketone. Even though this class of enzyme has been extensively studied, its mechanism of action is still being debated. Two mechanisms have been proposed: a radical mechanism and a nucleophilic mechanism. The radical mechanism is less generally accepted because no spectral or electron paramagnetic resonance evidence exists for the presence of a radical intermediate. The nucleophilic mechanism is more favored because it is supported by site-directed mutagenesis studies which mutated two tyrosine residues that were expected to increase the nucleophilicity of the substrates.
An important structural component of RNA that distinguishes it from DNA is the presence of a hydroxyl group at the 2' position of the ribose sugar. The presence of this functional group causes the helix to mostly take the A-form geometry, although in single strand dinucleotide contexts, RNA can rarely also adopt the B-form most commonly observed in DNA. The A-form geometry results in a very deep and narrow major groove and a shallow and wide minor groove. A second consequence of the presence of the 2'-hydroxyl group is that in conformationally flexible regions of an RNA molecule (that is, not involved in formation of a double helix), it can chemically attack the adjacent phosphodiester bond to cleave the backbone.
Sources: en.wikipedia.org
== Coups d'état == "...Thailand has experienced more coups d'état than any other country in contemporary history." according to The Washington Post. Since 1932, Thailand has had seven coup attempts and 12 successful coups (as of 2015).
Diet Dietary restriction and supplementation are key measures taken in several well-known metabolic disorders, including galactosemia, phenylketonuria (PKU), maple syrup urine disease, organic acidurias and urea cycle disorders. Such restrictive diets can be difficult for the patient and family to maintain, and require close consultation with a nutritionist who has special experience in metabolic disorders. The composition of the diet will change depending on the caloric needs of the growing child and special attention is needed during a pregnancy if a woman is affected with one of these disorders.
The concept of DNA-encoding was first described in a theoretical paper by Sydney Brenner and Richard Lerner in 1992 in which was proposed to link each molecule of a chemically synthesized entity to a particular oligonucleotide sequence constructed in parallel and to use this encoding genetic tag to identify and enrich active compounds. In 1993 the first practical implementation of this approach was presented by J Nielsen, S. Brenner and K. Janda and similarly by the group of M.A. Gallop. Brenner and Janda suggested to generate individual encoded library members by an alternating parallel combinatorial synthesis of the heteropolymeric chemical compound and the appropriate oligonucleotide sequence on the same bead in a “split-&-pool”-based fashion (see below). Since unprotected DNA is restricted to a narrow window of conventional reaction conditions, until the end of the 1990s a number of alternative encoding strategies were envisaged (i.e. MS-based compound tagging, peptide encoding, haloaromatic tagging, encoding by secondary amines, semiconductor devices.), mainly to avoid inconvenient solid phase DNA synthesis and to create easily screenable combinatorial libraries in high-throughput fashion. However, the selective amplificability of DNA greatly facilitates library screening and it becomes indispensable for the encoding of organic compounds libraries of this unprecedented size. Consequently, at the beginning of the 2000s DNA-combinatorial chemistry experienced a revival.
The flying primate hypothesis proposed that when adaptations to flight are removed, megabats are allied to primates and colugos by anatomical features not shared with microbats, and thus flight evolved twice in mammals. Genomic studies, however, have contradicted this hypothesis, strongly supporting the common ancestry of all bats and the single origin of mammal flight.
The vagina is a structure of animals in which the female is internally fertilized, rather than by traumatic insemination used by some invertebrates. Although research on the vagina is especially lacking for different animals, its location, structure and size are documented as varying among species. In therian mammals (placentals and marsupials), the vagina leads from the uterus to the exterior of the female body. Female placentals have two openings in the vulva; these are the urethral opening for the urinary tract and the vaginal opening for the genital tract. Depending on the species, these openings may be within the internal urogenital sinus or on the external vestibule. Female marsupials have two lateral vaginas, which lead to separate uteri, but both open externally through the same orifice; a third canal, which is known as the median vagina, and can be transitory or permanent, is used for birth. The female spotted hyena does not have an external vaginal opening. Instead, the vagina exits through the clitoris, allowing the females to urinate, copulate and give birth through the clitoris. In female canids, the vagina contracts during copulation, forming a copulatory tie. Female cetaceans have vaginal folds that are not found in other mammals. Monotremes, birds, reptiles and amphibians have a cloaca and is the single external opening for the gastrointestinal, urinary, and reproductive tracts. Some of these vertebrates have a part of the oviduct that leads to the cloaca. Chickens have a vaginal aperture that opens from the vertical apex of the cloaca.
Sources: en.wikipedia.org
It is a laboratory-made peptide that mimics growth hormone-releasing hormone. It prompts the pituitary gland to release growth hormone and has been studied mainly in adults with HIV-associated lipodystrophy.
Administered growth hormone supplies the hormone directly, while this peptide acts upstream by prompting the pituitary to release it. The indirect route preserves pulsatile secretion and some endogenous feedback, which changes the hormone and IGF-1 profile observed after treatment.
Reductions in visceral adipose tissue appear consistently in randomized trials of the approved population. Effects on peripheral fat, cardiovascular outcomes, and use outside that population are less well established.
It shares the 44-residue sequence of human GHRH but carries an added trans-3-hexenoyl group at its N-terminus. That addition does not occur in the natural hormone and serves mainly to resist enzymatic breakdown. The receptor target and signaling pathway remain the same.